Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.
about
Systemic therapies for pancreatic cancer--the role of pharmacogeneticsGenetic variations in radiation and chemotherapy drug action pathways and survival in locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapyProspective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumabPharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal CancerIdentification of novel germline polymorphisms governing capecitabine sensitivity.Common polymorphisms in angiogenesis.Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer.[Effects of cetuximab combined with celecoxib on apoptosis and KDR and AQP1 expression in lung cancer].Genotype-based selection of treatment for patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
P2860
Q27021716-B70AC497-72AF-47D1-886B-1A23D3255F69Q28536735-8C326FD3-2AB2-41BE-BF79-FA6627E32D84Q34825323-5D73A2B7-2F5C-47FD-8F49-2A1D9D093D9EQ35217801-1B824E09-4643-4E68-8002-4CA90AF89308Q35722688-A82D2EA9-CCD0-408C-B0F3-BF64FE153121Q36147462-5BE802F7-18F5-4A88-A091-D4D8BDDC91F9Q36526587-426FC676-5FB4-4B4B-BBC3-255045CDA82EQ37088265-F9FAB35D-D4A1-483C-AD7D-E4AD8D43582EQ38021921-0B4B08E2-5E32-432D-B25B-6928F5871BCDQ38166233-EC843D25-836E-4FEE-9D3F-6E700B93CA82Q38513661-2C7686BD-DDE8-42B2-9328-4B1A1A435EC4Q41608501-AA10964E-BF7B-4D30-9B11-8B52B2C28F4FQ46337863-347496EA-F161-4C49-9276-1CF4B889B5F8Q49960148-A3782967-290A-411F-A9CD-9ABEEC2E4417Q51058654-0BBAE121-3C21-42F2-AE13-03E18EFE4B3FQ54180020-2F6C0961-E31B-4DA8-931B-430EF5559343Q54196655-6E09CE36-BBD8-4BA3-A6E0-C64E926BF135
P2860
Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pharmacogenetic interaction an ...... metastatic colorectal cancer.
@en
Pharmacogenetic interaction an ...... metastatic colorectal cancer.
@nl
type
label
Pharmacogenetic interaction an ...... metastatic colorectal cancer.
@en
Pharmacogenetic interaction an ...... metastatic colorectal cancer.
@nl
prefLabel
Pharmacogenetic interaction an ...... metastatic colorectal cancer.
@en
Pharmacogenetic interaction an ...... metastatic colorectal cancer.
@nl
P2093
P2860
P356
P1433
P1476
Pharmacogenetic interaction an ...... n metastatic colorectal cancer
@en
P2093
C J A Punt
H Gelderblom
J A M Wessels
T van der Straaten
P2860
P304
P356
10.1093/ANNONC/MDQ572
P577
2010-11-03T00:00:00Z